Overview
Multiple sclerosis (MS) involving the brainstem can manifest with specific neurological deficits due to lesions in this critical region, affecting functions such as consciousness, cranial nerve activity, and autonomic regulation 1.Diagnosis
Neurological examination focusing on brainstem function (cranial nerves, coordination, reflexes) 1.
MRI imaging with emphasis on T2-weighted and gadolinium-enhanced sequences to identify brainstem lesions 1.
Evoked potentials (visual, brainstem auditory) to detect subclinical lesions 1.
CSF analysis for oligoclonal bands and IgG index, though less specific for brainstem involvement 1.Management
First-line treatments: Disease-modifying therapies (DMTs) such as interferons (e.g., IFN-β) and glatiramer acetate, aimed at reducing relapse rates and lesion formation 1.
Adjunctive therapies: Symptomatic treatment for specific deficits (e.g., physical therapy for coordination issues, medications for spasticity) 1.
Management of acute exacerbations: High-dose corticosteroids to reduce inflammation and improve acute symptoms 1.Special Populations
Pregnancy: Limited evidence; close monitoring and individualized treatment adjustments are recommended 1.
Elderly: Consideration of comorbidities and potential drug interactions when selecting DMTs 1.
Comorbidities: Tailor treatment plans to manage coexisting conditions without compromising MS therapy efficacy 1.Key Recommendations
Utilize MRI and evoked potentials for accurate diagnosis of brainstem involvement in MS 1 (Evidence: Strong).
Initiate first-line DMTs such as interferons or glatiramer acetate to manage disease progression 1 (Evidence: Strong).
Individualize treatment plans during pregnancy, considering both maternal and fetal safety 1 (Evidence: Moderate).References
1 Man S, Sanchez Duffhues G, Ten Dijke P, Baker D. The therapeutic potential of targeting the endothelial-to-mesenchymal transition. Angiogenesis 2019. link